High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases

Chinese Journal of Cancer

Volumn 33, Issue 2, 2014, Pages 96-104

  Zhu, Jian Fei ^a,b   Cai, Ling ^a,b   Zhang, Xue Wen ^a,c   Wen, Yin Sheng ^a,b   Su, Xiao Dong ^a,b   Rong, Tie Hua ^a,b   Zhang, Lan Jun ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Sun Yatsen Medical University   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Brain metastasis; Non small cell lung cancer; Plasma fibrinogen concentration; Platelet counts; Survival

Indexed keywords

CA 19-9 ANTIGEN; FIBRINOGEN;

ADULT; AGE; AGED; ARTICLE; BRAIN METASTASIS; CANCER PROGNOSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; SMOKING; SURVIVAL RATE; THROMBOCYTE COUNT; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; SMOKING; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84893496770     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10307     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin, 2008,58:71-96.
2. Kim SY, Kim JS, Park HS, et al. Screening of brain metastases with limited magnetic resonance imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients. J Korean Med Sci, 2005,20:121-126.
3. Cedres S, Nunez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer, 2011,12:172-179.
4. Barlesi F, Gimenez C, Torre JP, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med, 2004,98:357-362.
5. Biggerstaff JP, Seth N, Amirkhosravi A, et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastases. Clin Exp Metastases, 1999,17:723-730.
6. Buccheri G, Ferrigno D, Ginardi C, et al. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer, 1997, 33:50-55.
7. Pavey SJ, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis, 2001,12:51-58.
8. Seitz R, Rappe N, Kraus M, et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis, 1993,4:249-254.
9. Wojtukiewicz MZ, Zacharski LR, Moritz TE, et al. Prognostic significance of blood coagulation tests in carcinoma of the lung and colon. Blood Coagul Fibrinolysis, 1992,3:429-437.
10. Ghosh M, Aroor AR, Raghavan MR. Clinical utility of serum fibrinogen degradation products (FDP) in the diagnostic and prognostic evaluation of oral cancer. Ann Dent, 1990,49:11-12, 45.
11. Sawaguchi K, Hojo T, Nozaki S, et al. The clinical significance of thrombin-antithrombin III complex (TAT) and fibrinogen and fibrin degradation products (FDP) levels in ovarian cancer. Nihon Sanka Fujinka Gakkai Zasshi, 1992,44:73-78.
12. Halota W, Lapniewska E, Bulik F. The gamma globulin-fibrinogen index in the differential diagnosis of decompensated cirrhosis and primary liver cancer. Wiad Lek, 1990,43:118-121.
13. Lee JH, Ryu KW, Kim S, et al. Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumor. Hepatogastroenterology, 2004,51:1860-1863.
14. Duga S, Asselta R, Santagostino E, et al. Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. Blood, 2000,95:1336-1341.
15. Handagama PJ, Shuman MA, Bainton DF. In vivo defibrination results in markedly decreased amounts of fibrinogen in rat megakaryocytes and platelets. Am J Pathol, 1990,137:1393-1399.
16. Jones JM, Mcgonigle NC, Mcanespie M, et al. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer, 2006,53:97-101.
17. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood, 2000,96:3302-3309.
18. Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci, 2005,96:379-386.
19. Sahai E. Mechanisms of cancer cell invasion. Curr Opin Genet Dev, 2005,15:87-96.
20. Palumbo JS, Potter JM, Kaplan LS, et al. Spontaneous hematogenous and lymphatic metastases, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res, 2
21. Maeda R, Yoshida J, Ishii G, et al. The prognostic impact of cigarette smoking on patients with non-small cell lung cancer. J Thorac Oncol, 2011,6:735-742.
22. Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer, 2002,94:2698-2705.
23. Han F, Xia YF, Lu LX, et al. Analysis of prognostic factors for 63 patients with brain metastases from lung cancer after radiochemotherapy. Ai Zheng, 2002,21:1141-1144. [in Chinese]
24. Lee DS, Kim YS, Jung SL, et al. The relevance of serum carcinoembryonic antigen as an indicator of brain metastases detection in advanced non-small cell lung cancer. Tumour Biol, 2012.
25. Maeda R, Yoshida J, Ishii G, et al. The prognostic impact of cigarette smoking on patients with non-small cell lung cancer. J Thorac Oncol,2011,6:735-742.
26. Tuut M, Hense HW. Smoking, other risk factors and fibrinogen levels. evidence of effect modification. Ann Epidemiol,2001,11:232-238.
27. Ebert BL, Niemierko E, Shaffer K, et al. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist, 2003,8: 69-75.